Literature DB >> 34036437

Villoglandular adenocarcinoma of the uterine cervix: a systematic review and meta-analysis.

Anna K Dietl1, Matthias W Beckmann2, Konrad Aumann3,4.   

Abstract

PURPOSE: Villoglandular adenocarcinoma (VGA) of the uterine cervix has been classified as a rare subtype of cervical adenocarcinoma with good prognosis. A conservative surgical approach is considered feasible. The main risk factor is the presence of other histologic types of cancer. In this largest systematic review to date, we assess oncological outcomes associated with conservative therapy compared to those associated with invasive management in the treatment of stage Ia and Ib1 VGA.
METHODS: Case series and case reports identified by searching the PubMed database were eligible for inclusion in this review (stage Ia-Ib1).
RESULTS: A total of 271 patients were included in our literature review. 54 (20%) patients were treated by "conservative management" (conization, simple hysterectomy, and trachelectomy) and 217 (80%) by "invasive management" (radical hysterectomy ± radiation, hysterectomy, and radiation). Recurrences of disease (RODs) were found in the conservative group in two (4%) cases and in the invasive group in nine (4%) cases. There was no significant difference in disease-free survival (DFS) according to conservative or invasive treatment (p = 0.75). The histology of VGA may be complex with underlying usual adenocarcinoma (UAC) combined with VGA.
CONCLUSION: The excellent prognosis of pure VGA and the young age of the patients may justify the management of this tumor using a less radical procedure. The histological diagnosis of VGA is a challenge, and pretreatment should not be based solely on a simple punch biopsy but rather a conization with wide tumor-free margins.
© 2021. The Author(s).

Entities:  

Keywords:  Cervix; Conservative therapy; Invasive therapy; Review; Villoglandular adenocarcinoma

Year:  2021        PMID: 34036437     DOI: 10.1007/s00404-021-06077-9

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  51 in total

Review 1.  Villoglandular papillary adenocarcinoma of the cervix. Beware of a wolf in sheep's clothing.

Authors:  A Bouman; G J Oosterhuis; L Naudin ten Cate; G A van Doorn
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1999-12       Impact factor: 2.435

2.  Villoglandular adenocarcinoma of the cervix: clarity is needed on the histological definition for this difficult diagnosis.

Authors:  R D Macdonald; J Kirwan; K Hayat; C S Herrington; H Shawki
Journal:  Gynecol Oncol       Date:  2005-11-02       Impact factor: 5.482

3.  Prognostic factors influencing decisions about surgical treatment of villoglandular adenocarcinoma of the uterine cervix.

Authors:  Ha-Jeong Kim; Ji-Hee Sung; Eunjung Lee; Soomin Ahn; Sang Yong Song; Chel Hun Choi; Tae-Joong Kim; Byoung-Gie Kim; Duk-Soo Bae; Jeong-Won Lee
Journal:  Int J Gynecol Cancer       Date:  2014-09       Impact factor: 3.437

4.  International Endocervical Adenocarcinoma Criteria and Classification (IECC): correlation with adverse clinicopathological features and patient outcome.

Authors:  Anjelica Hodgson; Ekaterina Olkhov-Mitsel; Brooke E Howitt; Marisa R Nucci; Carlos Parra-Herran
Journal:  J Clin Pathol       Date:  2019-01-24       Impact factor: 3.411

5.  The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.

Authors:  H O Smith; M F Tiffany; C R Qualls; C R Key
Journal:  Gynecol Oncol       Date:  2000-08       Impact factor: 5.482

6.  Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women.

Authors:  Saskia Bulk; Otto Visser; Lawrence Rozendaal; René H M Verheijen; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2005-03-01       Impact factor: 7.396

7.  Villoglandular papillary adenocarcinoma of the uterine cervix: a diagnostic challenge.

Authors:  Jacob Korach; Ronit Machtinger; Tamar Perri; Daniel Vicus; Jacob Segal; Eddie Fridman; Gilad Ben-Baruch
Journal:  Acta Obstet Gynecol Scand       Date:  2009       Impact factor: 3.636

8.  Villoglandular papillary adenocarcinoma of the uterine cervix. A clinicopathologic analysis of 13 cases.

Authors:  R H Young; R E Scully
Journal:  Cancer       Date:  1989-05-01       Impact factor: 6.860

9.  Villoglandular adenocarcinoma of cervix: pathologic features, clinical management, and outcome.

Authors:  Peng Guo; Pengfei Liu; Junjun Yang; Tong Ren; Yang Xiang
Journal:  Cancer Manag Res       Date:  2018-09-26       Impact factor: 3.989

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.